Validation of the prognostic model for palliative radiotherapy in older patients with cancer.

IF 2.6 Q3 ONCOLOGY
Hyojung Park
{"title":"Validation of the prognostic model for palliative radiotherapy in older patients with cancer.","authors":"Hyojung Park","doi":"10.5306/wjco.v16.i3.101705","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Older patients are more likely to have a poor performance status and comorbidities. There is a reluctance to extensively investigate and treat older patients. As elderly individuals and patients with neoplasms each increase in number, palliative treatment of older patients is expected to grow as an issue.</p><p><strong>Aim: </strong>To investigated the role of palliative radiotherapy in older patients and patients who were expected to demonstrate a therapeutic effect.</p><p><strong>Methods: </strong>From February 2019 to February 2022, 33 patients aged ≥ 80 years underwent palliative radiotherapy. The prognosis in palliative care study predictor (PiPS), palliative prognostic index (PPI), and delirium-palliative prognostic score (D-PaP) models were used for prognosis prediction. D-PaP scores calculated according to the doctor's prediction of clinical prediction of survival (CPS) were excluded and then analyzed for comparison. Radiation was prescribed at a dose of 2.5-7 Gy per fraction, up to a median of 39 Gy<sub>10</sub> (range, 28-75 Gy<sub>10</sub>).</p><p><strong>Results: </strong>The median follow-up was 2.4 months (range, 0.2-27.5 months), and 28 patients (84.8%) showed subjective symptom improvements following treatment. The 2- and 6-month survival rates of all patients were 91.5% and 91.5%, respectively. According to regression analysis, the performance status index, symptom type, and radiation dose all showed no significant correlation with the treatment response. When survival was expected for > 55 days in the PiPS model, the 2-month survival rate was 94.4%. For patients with PPI and D-PaP-CPS values of 0-3.9 points, the 2-month survival rates were 90.0% and 100%, respectively. For patients with a score of ≥ 4 points, the 2-month survival rates were 37.5% and 0%, respectively.</p><p><strong>Conclusion: </strong>This study shows that the prognosis prediction model used in palliative care can be used to identify patients suitable for treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 3","pages":"101705"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866085/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i3.101705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Older patients are more likely to have a poor performance status and comorbidities. There is a reluctance to extensively investigate and treat older patients. As elderly individuals and patients with neoplasms each increase in number, palliative treatment of older patients is expected to grow as an issue.

Aim: To investigated the role of palliative radiotherapy in older patients and patients who were expected to demonstrate a therapeutic effect.

Methods: From February 2019 to February 2022, 33 patients aged ≥ 80 years underwent palliative radiotherapy. The prognosis in palliative care study predictor (PiPS), palliative prognostic index (PPI), and delirium-palliative prognostic score (D-PaP) models were used for prognosis prediction. D-PaP scores calculated according to the doctor's prediction of clinical prediction of survival (CPS) were excluded and then analyzed for comparison. Radiation was prescribed at a dose of 2.5-7 Gy per fraction, up to a median of 39 Gy10 (range, 28-75 Gy10).

Results: The median follow-up was 2.4 months (range, 0.2-27.5 months), and 28 patients (84.8%) showed subjective symptom improvements following treatment. The 2- and 6-month survival rates of all patients were 91.5% and 91.5%, respectively. According to regression analysis, the performance status index, symptom type, and radiation dose all showed no significant correlation with the treatment response. When survival was expected for > 55 days in the PiPS model, the 2-month survival rate was 94.4%. For patients with PPI and D-PaP-CPS values of 0-3.9 points, the 2-month survival rates were 90.0% and 100%, respectively. For patients with a score of ≥ 4 points, the 2-month survival rates were 37.5% and 0%, respectively.

Conclusion: This study shows that the prognosis prediction model used in palliative care can be used to identify patients suitable for treatment.

老年癌症患者姑息性放疗预后模型的验证。
背景:老年患者更有可能表现不佳并伴有合并症。人们不愿意对老年患者进行广泛的调查和治疗。随着老年人和肿瘤患者数量的增加,预计老年患者的姑息治疗将成为一个日益突出的问题。目的:研究姑息放疗在老年患者和有望显示治疗效果的患者中的作用。方法:从2019年2月至2022年2月,对33名年龄≥80岁的患者进行姑息放疗:从2019年2月至2022年2月,33名年龄≥80岁的患者接受了姑息放疗。采用姑息治疗研究预后预测因子(PiPS)、姑息预后指数(PPI)和谵妄-姑息预后评分(D-PaP)模型进行预后预测。根据医生的临床生存预测(CPS)计算出的 D-PaP 分数被排除在外,然后进行比较分析。放射治疗剂量为每分 2.5-7 Gy,中位数为 39 Gy10(范围为 28-75 Gy10):中位随访时间为 2.4 个月(0.2-27.5 个月),28 名患者(84.8%)在治疗后主观症状有所改善。所有患者的2个月和6个月生存率分别为91.5%和91.5%。根据回归分析,表现状态指数、症状类型和辐射剂量与治疗反应均无明显相关性。在 PiPS 模型中,当预期生存期大于 55 天时,2 个月生存率为 94.4%。对于 PPI 和 D-PaP-CPS 值为 0-3.9 分的患者,2 个月生存率分别为 90.0% 和 100%。对于评分≥4分的患者,2个月生存率分别为37.5%和0%:本研究表明,姑息治疗中使用的预后预测模型可用于识别适合治疗的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
585
期刊介绍: The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信